The effect of intestinal microbiota metabolites on HT29 cell line using MTT method in patients with colorectal cancer

Somayeh Jahani-Sherafat^{1, 2}, Masoumeh Azimirad¹, Hajieh Ghasemian-Safaei², Hadi Ahmadi Amoli³, Sharareh Moghim², Ghazal Sherkat⁴, Mohammad Reza Zali⁵

¹Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

³Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

⁴ Student Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran

⁵Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

Aim: The aim of this study was to evaluate the effect of intestinal microbiota metabolites in colorectal cancer patients on HT29 cell line using MTT assay.

Background: Colorectal cancer is one of the most common malignant tumors. Human guts harbor abundant microbes that adjust many aspects of the host physiology. Increasing studies suggest that gut microbiota play a significant role in the incidence and expansion of CRC, as a result of virulence factors, bacterial metabolites, or inflammatory pathways.

Methods: In this cross-sectional study, 60 biopsy samples including 30 cancerous and 30 adjacent healthy tissues were collected from patients with CRC during 2017. Biopsy samples were first cultured on Thioglycollate broth medium for 24hr after which the microbiota metabolites were filtered and stored at -20 C° for further evaluation. HT29 cells were treated by microbiota metabolites at different times (3, 6, 12, 18h) and its viability was assessed by MTT assay.

Results: The cells treated with microbiota metabolites showed increased viability and proliferation in time-dependent analysis by MTT assay, but there was not significant differences between the two groups.

Conclusion: It seems that microbial metabolites are able to induce proliferation and increase cell viability and thus induce colorectal cancer.

Keywords: Metabolites, Cell line, MTT, Colorectal cancer.

(Please cite as: Jahani-Sherafat S, Azimirad M, Ghasemian-Safaei H, Ahmadi Amoli H, Moghim SH, Sherkat Gh, et al. The effect of intestinal microbiota metabolites on HT29 cell line using MTT method in patients with colorectal cancer. Gastroenterol Hepatol Bed Bench 2019;12(Suppl.1):S74-S79).

Introduction

Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer death in the world (1). CRC is the fourth most common cancer in men following gastric, bladder, and prostate cancers and is the second most common cancer in women after breast cancer in Iran (2). The incidence of CRC in Iran is 7-8 people per 100,000 (3) and in young people or early CRC it has been reported as 20%. This might be due to a change in lifestyle and an increase in meat and fat consumption and a reduction in the consumption of grains and fiber in the Iranian diet (3). Since the cause of colorectal cancer is mostly related to environmental and epigenetic factors, it is important to study the effect of environmental factors on CRC progression.

Among environmental factors, microbiota have recently been given a very prominent role that can directly and indirectly facilitate the pathway of cancer by their structural components as well as their enzymes

Received: 29 September 2019 Accepted: 1 December 2019 Reprint or Correspondence: Sharareh Moghim, PhD. Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: moghim@med.mui.ac.ir ORCID ID: 0000-0002-7134-3145

and metabolites as well as the production of oxygen free radicals (4). Microbial imbalance in the gut (dysbiosis) can play a key role in altering the composition of intestinal bacterial components. High production of some harmful bacterial enzymes, alteration in the distribution of bacterial communities (commensal bacteria), changes in bacterial metabolic activity (SCFA), the metabolism of bile acids, and loss of protection against dietary carcinogens are the result of dysbiosis (5). (6). Many factors, including antibiotic usage, psychological and physical stress, radiation, altered bowel motility and diet can alter the digestive ecosystem and thus change the bacterial composition (7, 8). On the other hand, some intestinal anaerobic bacteria, such as Clostridium and bacterioides, as the predominant population of the intestinal microbiota, produce bacterial metabolites such as bile acids, fatty β-glucosidase. acids. β-galactosidase. reductase. decarboxylase, and protease which can also increase the risk of colorectal cancer (9). It has been reported that about 30% of Clostridium were capable of producing high levels of β -galactosidase enzymes (10). The level of this enzyme has been reported to be far higher in the stools of patients with colorectal cancer as compared with healthy controls (11). Azoreductase can be involved in the development of cancer by producing toxic substances from dyes and drugs. This enzyme is active in bacteria such as Bacteroides fragillis and Beta thioatomicron and some Clostridium such as Clostridium perfringens (12). Some bacteria, such as Bacteroides, Streptococcus, and Clostridium, produce high levels of proteolytic enzymes, such as proteasomes, which can bind to intestinal epithelial cells by specific receptors and cause binding, biofilm formation, and invasion of these cells. This is a first step towards the disease, which is inflammation (13, 14). By considering previous studies on the role of bacteria and metabolites produced by them, it may be possible to find a link between CRC and metabolites produced by the gut microbiota. Multiple in vitro tests are trying to assess the toxicity of some compounds. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) is one of the most commonly used assays to assess the toxicity of some agents (15). This method is reliable for investigation of the influence of microbial metabolites on cytotoxicity or viability and cell proliferation (16). The aim of this

study was to evaluate the effect of intestinal microbiota metabolites in colorectal cancer patients on HT29 cell line using MTT assay.

Methods

Samples and preparation of microbiota metabolites:

Thirty specimens of cancerous tissue and 30 specimens of adjacent healthy tissue were collected from patients with colon cancer during surgery. Tissue samples were transferred to the microbiology laboratory under anaerobic conditions in broth thioglycolate medium to study the metabolic effects of the bacteria on the cell culture medium. Samples were homogenized manually using a tissue grinder and then incubated under completely anaerobic conditions for 24 hours at 37 °C. It was then stored using a 0.22 μ m syringe filter and a bacterial-free material filter was stored at -20 °C for the effect of bacterial metabolites study.

Cell culture

To investigate the effect of bacterial metabolites on intestinal cells, the HT29 cell line originating from adenocarcinoma cells was used. This cell line was purchased from the Pasteur Institute of Iran. The culture medium used was H-DMEM containing 10% FBS (Sigma-Aldrich), 2% non-essential amino acid (NEAA, Gibco), and 1% antibiotics. The cells were passaged for several generations in special flasks using trypsin-EDTA (0.25%). Trypsinized cells were incubated at 37 °C and 5% CO2 atmosphere.

MTT test

To investigate the effect of cytotoxicity or proliferation of metabolites obtained from microbiota of CRC patients, cell viability was assessed using MTT Assay kit (Sigma, America) after complete growth of HT29 cells for 3 days. A total of 100 μ of filtered bacterial metabolites was shed on the cells and incubated at 3, 6, 12, and 18 hrs at 37° C as well as atmosphere containing 5% Co2. Thereafter, 100 μ L of MTT solution was added to the plates and incubated for 4 hours at 37°C and 5% Co2 atmosphere. Then, 1 ml of the solubilization solution was added to the plates and incubated 15-20 min at 37° C with a 5% Co2 atmosphere. Next, reads at 570 nm and 650 nm, as a reference wavelength, using ELISA Reader, (ELX808, Biotek). Cell viability was calculated using the

following formula: Viability (%) = (OD test/OD control) x100

Statistical analysis

Statistical calculations were performed to compare the mean and standard deviation using SPSS Ver.20 and t-Test with P <0.05 considered statistically significant (P <0.05).

Results

The cultures of HT29 cells were treated with metabolites after cell growth and differentiation (Figure 1). MTT assay was performed in 3, 6, 12, and 18hr of simultaneous microbiota cell and metabolite culture (Figure 1).

The cytotoxic effect of bacterial metabolites on the HT29 cell line was assessed by ELISA reader on

differentiated cell supernatants. These results confirm the lack of toxic effects of the investigated metabolites on differentiated cell lines at 6, 3, 12, 18 h (Figure 2). As depicted in Figure 5, the lowest percentage of cells exposed to metabolites and the highest proliferation rate were obtained at 3 h and 12 h, respectively. There was no significant difference between the results of cancerous tissue and adjacent healthy tissue (p =0.1).

Discussion

Cancer is one of the leading causes of death worldwide. According to WHO projections by 2030, more than 21 million new cancer cases and more than 13 million cancer deaths will occur globally. Meanwhile, colon cancer is also considered to be the third most common cancer in the world (1).




Figure 1. HT-29 cell line; a: before treatment with bacterial metabolites, a, b: Untreated cells during testing on 24-well plates, c: Differentiated cells ready for treatment by bacterial metabolites, d: Cells treated with bacterial metabolites for 24 hours




Figure 2. Comparison of the mean cell viability with microbiota metabolites at different time points in cancer and normal samples

Microbial pathogens are known to initiate 20% of tumorigenesis and a considerable number of malignancies are associated with dysbiosis (17). Intestinal microbiota changes in patients with colorectal cancer have been reported in many studies, but what is controversial is whether the cancer is a product of a change in the microbiota or whether cancer progression causes changes in the natural microbiome. There is strong evidence for both theories (17, 18). The gut microbiota can promote CRC through a variety of processes, including inducing a chronic inflammatory disease or immune response, altering stem cell of toxic metabolites, dynamics, biosynthesis genotoxins, influencing host metabolism. and preventing cancer by producing metabolites and enzymes (20, 21).

In the present study, the role of intestinal microbiota in CRCs was investigated on the lethality or cellular proliferation on HT29 cells. Based on the results, the microbiota metabolites of these patients induced cell proliferation in cell culture compared to blank cell culture. The mean percentage of cellular proliferation in metabolites obtained from tumor specimens was slightly higher than in normal tissue samples but no significant difference was observed between the two

groups. Both normal and tumor specimens were taken from one patient; although some studies have reported differences between microbiota in cancer and normal tissue, most studies have indicated that the structure of the gut microbiota often forms before three years of age and has a stable structure throughout their lives (22). Certain factors such as antibiotic use, specific diet, chemotherapy, etc. can disrupt the gut microbiota structure (23). In a study conducted by Sadeghi and colleagues in 2018 on chromogenic acid along with microbial metabolites from fruits and vegetables, it was found that these microbial metabolites have an antiproliferative effect on the caco2 cell line and induced apoptosis in cells after 24 hours (16). In this study, anticancer agents were used and their results were in line with our results. In another study, Shi et al. (2016) studied the effects of LPS (lipopolysaccharide) on inflammatory factors using MTT assay. They found that LPS incubation time had a significant relationship with cellular proliferation factors. superoxide dismutase (SOD) levels were not significantly different between the experimental and control groups, but the catalase enzyme was significantly reduced. Cell proliferation at concentrations of 0.1 and 1 µg/L and 6 h incubation decreased cell proliferation, and this result is probably

because of toxic concentration of LPS to cells thus causing cell death (24). Studies have shown that LPS causes oxidative damage and has been widely used to create animal models of inflammation and bacterial infection (25).

In a study examining effect of fecal filtered fluid on caco2 cell culture using comet test, Venturi and colleagues observed that in normal samples they had no detrimental effect on DNA breakage, but in samples with intestinal problems such as intestinal polyps, DNA breakage was observed. (26). DNA breakdown can cause carcinogenic mutations in the cell and as these mutations accumulate, the cells move toward cancer. On the other hand, some bacterial metabolites such as Enterococcus faecalis, Enterotoxin bacteroides Fragillis or fadA in Fusobacterium nucleatum have the ability to break down DNA and thus induce intestinal cell pre-proliferation and increase in intestinal microbiota in microbiota studies (27).

Given the effect of bacterial metabolites isolated from CRC patients on increasing proliferation of the HT29 cell line, it seems that bacterial metabolites may play a central role in the relationship between the microbiota and associated colon cancer. Bacteria can alter the expression of genes involved in carcinogenesis during infection or their inflammation or directly by the production of intestinal microbiota metabolites. More studies are required to study the role of gut microbiota in CRC patients.

Conflict of interests

The authors declare that they have no conflict of interest.

References

1.Jahani-Sherafat S, Alebouyeh M, Moghim S, Ahmadi Amoli H, Ghasemian-Safaei H. Role of gut microbiota in the pathogenesis of colorectal cancer; a review article. Gastroenterol Hepatol Bed Bench 2018;11:101-09.

2.Mansouri V, Rezaei Tavirani M, Rezaei Tavirani S. Gene screening of colorectal cancers via network analysis. Gastroenterol Hepatol Bed Bench 2019;12:149-54.

3.Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F, et al. Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry. Cancer Lett 2006;240:143-7.

4.Serban DE. The gut microbiota in the metagenomics era: sometimes a friend, sometimes a foe. Roum Arch Microbiol Immunol2011;70:134-40.

5.Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009;4:e6026

6.Sharma R, Young C, Mshvildadze M, Neu J. Intestinal Microbiota Does It Play a Role in Diseases of the Neonate? Neoreviews 2009;10:e166-e79.

7.Marchesi JR, Dutilh BE, Hall N, Peters W, Roelofs R, Boleij A, et al. Towards the human colorectal cancer microbiome. PloS one 2011;6:e20447.

8.Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011;5:71-86.

9.Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241-59.

10.Dabek M, McCrae SI, Stevens VJ, Duncan SH, Louis P. Distribution of β -glucosidase and β -glucuronidase activity and of β -glucuronidase gene gus in human colonic bacteria. FEMS Microbiol Ecol 2008;66:487-95.

11.Kim DH, Jin YH. Intestinal bacterial β -glucuronidase activity of patients with colon cancer. Arch Pharm Res 2001;24:564-7.

12.Wang RF, Chen H, Paine DD, Cerniglia CE. Microarray method to monitor 40 intestinal bacterial species in the study of azo dye reduction. Biosens Bioelectron 2004;20:699-705.

13.Carroll IM, Maharshak N. Enteric bacterial proteases in inflammatory bowel disease-pathophysiology and clinical implications. World J Gastroenterol 2013;19:7531.

14.Jahani-Sherafat S, Azimirad M, Alebouyeh M, Ahmadi Amoli H, Hosseini P, Ghasemian-Safaei H, et al. The rate and importance of Clostridium difficile in colorectal cancer patients. Gastroenterol Hepatol Bed Bench 2019;12:358-63.

15.Śliwka L, Wiktorska K, Suchocki P, Milczarek M, Mielczarek S, Lubelska K, et al. The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions. PLoS One 2016;11:e0155772.

16.Sadeghi Ekbatan Sh, Li XQ, Ghorbani M, Azadi B, Kubow S. Chlorogenic Acid and Its Microbial Metabolites Exert Anti-Proliferative Effects, S-Phase Cell-Cycle Arrest and Apoptosis in Human Colon Cancer Caco-2 Cells. Int J Mol Sci 2018;19.

17.Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, et al. Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers 2019;11.

18.Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation and cancer. Cancer J 2014;20:181-9.

19.Blumberg R, Powrie F. Microbiota, disease, and back to health: a metastable journey. Sci Transl Med 2012;4:137-7.

20.Tsilimigras MC, Fodor A, Jobin C. Carcinogenesis and therapeutics: the microbiota perspective. Nat Microbiol 2017;2:17008.

Gastroenterol Hepatol Bed Bench 2019;12(Suppl.1):S74-S79

21.Cani PD, Plovier H, Van Hul M, Geurts L, Delzenne NM, Druart C, et al. Endocannabinoids—at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol 2016;12:133.

22.Turroni F, Peano C, Pass DA, Foroni E, Severgnini M, Claesson MJ, et al. Diversity of bifidobacteria within the infant gut microbiota. PLoS One 2012;7:e36957.

23.Carman RJ, Simon MA, Fernández H, Miller MA, Bartholomew MJ. Ciprofloxacin at low levels disrupts colonization resistance of human fecal microflora growing in chemostats. Regul Toxicol Pharmacol 2004;40:319-26.

24.Shi H, Guo Y, Liu Y, Binlin Shi, Guo X, Jin L, Yan S. The in vitro effect of lipopolysaccharide on proliferation,

inflammatory factors and antioxidant enzyme activity in bovine mammary epithelial cells. Animal Nutr 2016;99-104.

25.Wang DX. A research review: poisonous bacteria lipopolysaccharide and development. Foreign Med Sci Hyg. 2008; 35:170-3

26.Venturi M, Hambly RJ, Glinghammar B, Rafter JJ, Rowland IR. Genotoxic activity in human faecal water and the role of bile acids: a study using the alkaline comet assay. Carcinogenesis 1997;18:2353-9.

27.Tilg H, Adolph TE, Gerner RR, Moschen AR. The intestinal microbiota in colorectal cancer. Cancer Cell 2018;33:954-964.